Nociceptin/orphanin FQ exacerbates excitotoxic whitematter lesions in the murine neonatal brain

Journal of Clinical Investigation

Volumn 107, Issue 4, 2001, Pages 457-466

  Laudenbach, V ^a   Calo, G ^a   Guerrini, R ^a   Lamboley, G ^a   Benoist, J F ^a   Evrard, P ^a   Gressens, P ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOMORPHIN 1; IBOTENIC ACID; NALOXONE; NOCICEPTIN; OPIATE RECEPTOR;

ANIMAL TISSUE; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; ENCEPHALOMALACIA; HISTOPATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035116687     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9716     Document Type: Article

References (53)

1. Periventricular leukomalacia: Risk factors revisited
2. The changing panorama of cerebral palsy: Bilateral spastic forms in particular
3. Endoroxin leucoencephalopathy in the telencephalon of the newborn kitten
4. Predictors of low and very low birth weight and the relation of these to cerebral palsy
5. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies
6. Environmental and genetic determinants of neural migration and postmigratory survival
7. Vasoactive intestinal peptide prevents excito-toxic cell death in the murine developing brain
8. Brain damage in preterm newborns: Might enhancement of developmentally regulated endogenous protection open a door for prevention?
9. Physiological and patho-physiological roles of excitatory amino acids during central nervous system development
10. Effect of ibotenate on brain development: An excitotoxic mouse model of microgyria and posthypoxic-like lesions
11. Regulation of neuroprotective action of vasoactive intestinal peptide in the murine developing brain by protein kinase C and mitogen-activated protein kinase cascades: In vivo and in vitro studies
12. Prevention by magnesium of excitotoxic neuronal death in the developing brain: An animal model for clinical intervention studies
13. Glycine antagonist and NO synthase inhibitor protect the developing mouse brain against neonatal excitotoxic lesions
14. Magnesium deficiency-dependent audiogenic seizures (MDDASs) in adult mice: A nutritional model for discriminatory screening of anticonvulsant drugs and original assessment of neuroprotection properties
15. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium
16. Iron supplementation aggravates periventricular cystic white matter lesions in newborn mice
17. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions
18. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
19. Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor
20. Nociceptin/orphanin FQ and the opioid receptorlike ORL1 receptor
21. Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems
22. Regulation of nociceptin/orphanin FQ gene expression by neuropoietic cytokines and neurotrophic factors in neurons and astrocytes
23. Activity and cyclic AMP-dependent regulation of nociceptin/orphanin FQ gene expression in primary neuronal and astrocyte cultures
24. Cyclic AMP analogs induce synthesis, processing, and secretion of prepro nociceptin/orphanin FQ-derived peptides by NS20Y neuroblastoma cells
25. Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ
26. The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line
27. Orphanin FQ/ nociceptin modulates glutamate- and kainic acid-induced currents in acutely isolated rat spinal dorsal horn neurons
28. The NMDA receptor antagonist, NPC 12626, reduces the pronociceptive effects of orphanin FQ and kappa opiate antinociception in the land snail, Cepaea nemoralis
29. Attenuation of nociceptin/orphanin FQ-induced signaling by N-methyl-D-aspartate in neuronal cells
30. Nociceptin induced inhibition of K+ evoked glutamate release from rat cerebrocortical slices
31. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay
32. Les morphiniques sont-ils en cause dans la leucomalacie périventriculaire du prématuré?
33. Long-term evolution of excitotoxic cortical dysgenesis induced in the developing rat brain
34. Characterization of nociceptin receptors modulating locomotor activity in mice
35. Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain
36. Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites
37. Pharmacology of nociceptin and its receptor: A novel therapeutic target
38. Nociceptin, Phe(1)psi-nociceptin(1-13), nocistatin and prepronociceptin(154-181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro
39. Characterization of [Nphe1]NC(1-13)NH2, a novel selective nociceptin receptor antagonist
40. Characterization of [Nphe(1)]nociceptin (1-13)NH(2), a new selective nociceptin receptor antagonist
41. Address and message sequences for the nociceptin receptor: A structure-activity study o f nociceptin-(1-13)-peptide amide
42. Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice
43. Nocistatin, a peptide that blocks nociceptin action in pain transmission
44. Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist
45. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system
46. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes
47. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat
48. Prenatal inhibition of intestinal vasoactive peptide and cerebral excitatory lesions in the newborn mouse
49. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis
50. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter
51. News on glutamate receptors in glial cells
52. Effects of kappa- and mu-opioid receptor agonists on Ca2+ channels in neuroblastoma cells: Involvement of the orphan opioid receptor
53. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library